Products and Services offered

Dr. Jim Hu is a urologic oncologist with his undergraduate degree in Economics, his Master's in Public Health in Health Policy and Management from Johns Hopkins University, and his Medical Degree from Baylor College of Medicine. He completed his Urology Residency at the David Geffen School of Medicine at UCLA and his Robotic Surgery/Urologic Oncology Fellowship in 2004 at City of Hope National Medical Center. He began his career as the Director of Robotic and Minimally Invasive Surgery at Brigham and Women's Hospital and Instructor at Harvard Medical School and was quickly promoted to Director of the Prostate Cancer Program at Dana Farber/Harvard Cancer Center and Associate Professor. He was then recruited back to the David Geffen School of Medicine at UCLA as the Henry Singleton Chair of Robotic and Minimally Invasive Surgery, where he led the minimally invasive prostate cancer, kidney cancer, and kidney donor nephrectomy program. He was promoted to Professor before joining the faculty at Weill Cornell Medical College in 2015 as the Director of the LeFrak Center for Robotic Surgery and the Ronald P. Lynch Chair in Urologic Oncology. He currently serves as the Vice-Chair of Clinical Research, Chair of Quality and Patient Safety, and the Course Director for Urology Grand Rounds. Dr. Hu is an internationally renowned surgical innovator and health services researcher. His comparative effectiveness research interests have been funded by the Department of Defense, the National Cancer Institute, and the Livestrong Foundation. He is currently the contact principal investigator on two National Cancer Institute R0-1 randomized clinical trials investigating novel, potentially practice-changing approaches to prostate biopsy and radical prostatectomy. He is also the contact principal investigator on two Patient-Centered Outcomes Research Institute (PCORI) awards investigating prostate biopsy and comparative effectiveness of focal therapy, stereotactic body radiation therapy vs. conventional prostate cancer therapies. He has been awarded more than $12 million in peer-reviewed funding, and he has authored more than 300 peer-reviewed papers. His discoveries have been published in the most prestigious and exclusive medical journals, such as the New England Journal of Medicine, the Journal of the American Medical Association, and the Journal of Clinical Oncology, as well as featured in the New York Times, Wall Street Journal, and Boston Globe. In addition, Dr. Hu has published the most advances/videos of technical modifications internationally in European Urology Surgery in Motion to improve prostate and kidney cancer surgical outcomes. Dr. Hu has performed over 4000 laparoscopic, robotic and open procedures.